Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed this Current Report on May 20, 2022, reporting events occurring on May 18, 2022. The filing concerns a private placement of Class A common stock and warrants; it does not provide quarterly or annual operating results.
Transaction and Key Financial Metrics
- Gross proceeds: Approximately $30.0 million.
- Securities issued: 4,054,055 shares of Class A common stock and warrants to purchase up to 4,054,055 additional shares.
- Purchase price: $7.40 per share and accompanying warrant.
- Warrant exercise price: $8.25 per share.
- Warrant term: Immediately exercisable and expiring May 20, 2027.
- Use of proceeds: Working capital and general corporate purposes.
- Fees and net proceeds: The filing states that customary placement fees are payable to the placement agent but does not provide the resulting net proceeds.
- Revenue, profit, cash flow, margins, debt and liquidity: The filing does not provide clear values or updates for these metrics.
Material Changes and Capital Structure Effects
The financing increases shares outstanding by 4,054,055 shares and could result in up to 4,054,055 additional shares if the warrants are exercised, creating potential dilution to existing stockholders. The warrants include customary anti-dilution adjustments and a beneficial ownership exercise limitation of 4.99%, which may be increased to 9.99% by the holder.
The securities were sold in a private placement under Section 4(a)(2) of the Securities Act and Regulation D and were not registered under the Securities Act or applicable state securities laws at issuance.
Guidance, Outlook, Risks and Unusual Items
- Celularity entered into a registration rights agreement covering resale of the issued shares and shares issuable upon warrant exercise.
- The company agreed to file a resale registration statement within 10 days after the May 20 closing and to use commercially reasonable efforts to obtain effectiveness within 20 days if there is no SEC review, or within 45 days if the SEC reviews the filing.
- The securities cannot be offered or sold in the United States absent registration or an applicable exemption.
- The transaction was subject to customary closing conditions; the filing states that closing occurred on May 20, 2022.
- A.G.P./Alliance Global Partners acted as sole placement agent and will receive customary placement fees.
- The filing provides no operating guidance or detailed management outlook. Investors should consider execution risk related to the intended use of proceeds, potential dilution, warrant exercise dynamics and the timing of resale registration.
Important Facts for Investors to Verify
- Verify the final number of shares outstanding after the private placement and the potential fully diluted share count including warrants.
- Review the securities purchase agreement, warrant form, registration rights agreement and placement agency agreement filed as Exhibits 10.1 through 10.4.
- Confirm the final placement fees and net cash proceeds received by Celularity.
- Monitor the filing and effectiveness of the resale registration statement and any related SEC comments.
- Review subsequent filings for the impact of the financing on liquidity, capital needs, operating results and warrant exercises.